Targeted in vivo delivery of EGFR siRNA inhibits ovarian cancer growth and enhances drug sensitivity
OPEN Scientific reports | 8 Nov 2016
M Satpathy, R Mezencev, L Wang and JF McDonald
A functionalized nanohydrogel siRNA delivery system and a mouse model of serous ovarian cancer were used to test predictions from previous cell line studies that knockdown of EGFR (epidermal growth factor receptor) may be of clinical significance in the treatment of epithelial tumors especially with respect to the enhancement of platinum based therapies. Our results support these predictions and suggest that targeted delivery of EGFR siRNA may be an effective strategy for the treatment of ovarian and other epithelial tumors associated with elevated levels of EGFR and especially those demonstrating resistance to platinum-based therapies.
* Data courtesy of Altmetric.com